Close
Help





JOURNAL

Biomarker Insights

Changes in Alternative Splicing as Pharmacodynamic Markers for Sudemycin D6

Submit a Paper


Biomarker Insights 2017:12 1177271917730557

Short Report

Published on 12 Sep 2017

DOI: 10.1177/1177271917730557


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Biomarker Insights

Abstract

Objective:

The aim of the study was to define pharmacodynamic markers for sudemycin D6, an experimental cancer drug that changes alternative splicing in human blood.

Methods:

Blood samples from 12 donors were incubated with sudemycin D6 for up to 24 hours, and at several time points total RNA from lymphocytes was prepared and the pre-messenger RNA (mRNA) splicing patterns were analyzed with reverse transcription-polymerase chain reaction.

Results:

Similar to immortalized cells, blood lymphocytes change alternative splicing due to sudemycin D6 treatment. However, lymphocytes in blood respond slower than immortalized cultured cells.

Conclusions:

Exon skipping in the DUSP11 and SRRM1 pre-mRNAs are pharmacodynamic markers for sudemycin D6 treatment and show effects beginning at 9 hours after treatment.



Downloads

PDF  (770.72 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

XML   (43.62 KB XML FORMAT)

BibTex citation   (BIBDESK, LATEX)





Quick Links


New article and journal news notification services